Related references
Note: Only part of the references are listed.Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab
George Pentheroudakis et al.
CLINICAL COLORECTAL CANCER (2019)
VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease
Vijay Chaitanya Ganta et al.
CIRCULATION RESEARCH (2017)
Circulating levels of angiogenesis-related growth factors in breast cancer: a study to profile proteins responsible for tubule formation
Gemma A. Barron et al.
ONCOLOGY REPORTS (2017)
Bevacizumab in breast cancer: a targeted therapy still in search of a target population
Douglas K. Marks et al.
SEMINARS IN ONCOLOGY (2017)
Anti-Mullerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study
Elisabeth Trapp et al.
BREAST (2017)
Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
Zhexuan Lin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial
L. Schroeder et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2016)
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
D. Zhao et al.
ONCOGENE (2015)
The role of VEGF165b in pathophysiology
Maria Peiris-Pages
CELL ADHESION & MIGRATION (2012)
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors
Lauren L. C. Marotta et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells
J. Ciura et al.
MOLECULAR BIOLOGY REPORTS (2010)
The anti-angiogenic isoforms of VEGF in health and disease
Yan Qiu et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia
Victoria L. Bills et al.
CLINICAL SCIENCE (2009)
Therapeutic potential of manipulating VEGF splice isoforms in oncology
Emma S. Rennel et al.
FUTURE ONCOLOGY (2009)
VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma:: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
A. H. R. Varey et al.
BRITISH JOURNAL OF CANCER (2008)
The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
E. S. Rennel et al.
BRITISH JOURNAL OF CANCER (2008)
Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity
Harukiyo Kawamura et al.
CANCER RESEARCH (2008)
p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors:: VEGF165b downregulation as a marker of poor prognosis
Raquel Diaz et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma
R. O. Pritchard-Jones et al.
BRITISH JOURNAL OF CANCER (2007)
Roots and stems: stem cells in cancer
K Polyak et al.
NATURE MEDICINE (2006)
VEGF165b, an inhibitory vascular endothelial growth factor splice variant:: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression
J Woolard et al.
CANCER RESEARCH (2004)
Share Paper
